HUMALOG MIX 75/25 PEN (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1999.
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
HUMALOG MIX 75/25 PEN is a rapid-acting insulin lispro analog in a fixed 75/25 ratio of intermediate to rapid-acting insulin, administered by subcutaneous injection. It treats both Type 1 and Type 2 Diabetes Mellitus by lowering blood glucose through stimulation of peripheral glucose uptake and inhibition of hepatic glucose production. The formulation combines the convenience of a pre-mixed ratio with the speed of insulin lispro's rapid onset.
With LOE approaching and competitive pressure at 30%, this product is in a defensive posture; career opportunities focus on market protection and managed decline rather than growth initiatives.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG MIX 75/25 PEN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HUMALOG MIX 75/25 offers limited career acceleration due to LOE approaching and competitive pressure; roles center on defending market share against superior-mechanism competitors rather than growth initiatives. This position suits professionals comfortable with mature product management and skilled in navigating reimbursement complexity during patent cliff transition.